Literature DB >> 28280069

Duloxetine: urinary incontinence and marketing authorization incontinence.

Alain Braillon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28280069      PMCID： PMC5334012          DOI： 10.1503/cmaj.732561

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  4 in total

1.  Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports.

Authors:  Emma Maund; Louise Schow Guski; Peter C Gøtzsche
Journal:  CMAJ       Date:  2016-11-14       Impact factor: 8.262

Review 2.  Hepatic effects of duloxetine-I: non-clinical and clinical trial data.

Authors:  Joachim Wernicke; Beth Pangallo; Fujun Wang; Isabelle Murray; Judith W Henck; Mary Pat Knadler; Deborah N D'Souza; Jack P Uetrecht
Journal:  Curr Drug Saf       Date:  2008-05

Review 3.  Towards better patient care: drugs to avoid in 2016.

Authors: 
Journal:  Prescrire Int       Date:  2016-04

Review 4.  Clinical management of urinary incontinence in women.

Authors:  Lauren Hersh; Brooke Salzman
Journal:  Am Fam Physician       Date:  2013-05-01       Impact factor: 3.292
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.